Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and its role in the development of de novo resistance to targeted therapies has become increasingly apparent. However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear. Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells. These changes are guided to ensure DNA repair and the correct entrance and exit from mitosis in the presence of chemotherapy. We used conditioned media (CM) from normal-colonic fibroblasts and paired CAFs to assess dose response curves of oxaliplatin and 5-fluorouracil, separately or combined, compared with standard culture medium. We also evaluated a colony-forming assay and cell death to demonstrate the protective role of CAF-CM. Immunofluorescence confirmed the translocation of AKT, P38 and Survivin to the nucleus induced by CAF-soluble factors. We also have shown that STAT3 or P38 inhibition provides a promising strategy for overcoming microenvironment-mediated resistance. Conversely, pharmacologic AKT inhibition induces an antagonistic effect that relieves a cMET and STAT3-mediated compensatory feedback that might explain the failure of AKT inhibitors in the clinic so far.

[1]  E. Musulen,et al.  PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines , 2015, PloS one.

[2]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[3]  R. Sanz-Pamplona,et al.  Intrinsic cancer subtypes-next steps into personalized medicine , 2015, Cellular Oncology.

[4]  R. Sanz-Pamplona,et al.  Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information , 2014, Molecular oncology.

[5]  長﨑 高也.  Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis : anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction , 2014 .

[6]  A. Takahashi,et al.  The BRCA2 gene is a potential molecular target during 5-fluorouracil therapy in human oral cancer cells. , 2014, Oncology reports.

[7]  B. Zhai,et al.  Up‐regulation of survivin by AKT and hypoxia‐inducible factor 1α contributes to cisplatin resistance in gastric cancer , 2014, The FEBS journal.

[8]  Y. Miao,et al.  Stromal–Epithelial Crosstalk Provides a Suitable Microenvironment for the Progression of Ovarian Cancer Cells in Vitro , 2013, Cancer investigation.

[9]  A. G. de Herreros,et al.  Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature , 2013, Clinical Cancer Research.

[10]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[11]  C. Arteaga,et al.  Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation , 2013, Breast Cancer Research.

[12]  S. Groshen,et al.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. , 2013, Cancer research.

[13]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[14]  A. Martelli,et al.  The emerging multiple roles of nuclear Akt. , 2012, Biochimica et biophysica acta.

[15]  J. Delord,et al.  Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death , 2012, International journal of molecular sciences.

[16]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[17]  A. Opstal,et al.  Inhibition of protein kinase B activity induces cell cycle arrest and apoptosis during early G1 phase in CHO cells , 2012, Cell biology international.

[18]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[19]  R. Salazar,et al.  Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. , 2011, Neoplasia.

[20]  P. D. De Angelis,et al.  DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. , 2011, International journal of oncology.

[21]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[22]  Chi-Ying F. Huang,et al.  Insulin-like growth factor 1 mediates 5-fluorouracil chemoresistance in esophageal carcinoma cells through increasing survivin stability , 2011, Apoptosis.

[23]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[24]  C. Garlanda,et al.  The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker , 2010, Journal of Translational Medicine.

[25]  S. Leung,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation Subcellular Localization of Activated AKT in Estrogen Receptor-and Progesterone Receptor-Expressing Breast Cancers Potential Clinical Implications , 2010 .

[26]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[27]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[28]  K. Pienta,et al.  CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation* , 2008, Journal of Biological Chemistry.

[29]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[30]  B. Zhivotovsky,et al.  Death through a tragedy: mitotic catastrophe , 2008, Cell Death and Differentiation.

[31]  B. Hemmings,et al.  PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. , 2008, Molecular cell.

[32]  T. Kowalik,et al.  Activated checkpoint kinase 2 provides a survival signal for tumor cells. , 2006, Cancer research.

[33]  D. Altieri.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions. , 2006, Current opinion in cell biology.

[34]  S. Wheatley,et al.  Separating the Anti-apoptotic and Mitotic Roles of Survivin* , 2006, Journal of Biological Chemistry.

[35]  Ping Zhang,et al.  Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line , 2006, BMC Cancer.

[36]  D. Rouillard,et al.  Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. , 2006, Anticancer research.

[37]  Wei Zhang,et al.  Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. , 2005, The American journal of pathology.

[38]  T. Koyama,et al.  p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide , 2005, Apoptosis.

[39]  T. Nagayasu,et al.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors , 2005, Journal of Clinical Pathology.

[40]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[41]  M. Uhler,et al.  Phosphatidylinositol 3‐kinase and Akt effectors mediate insulin‐like growth factor‐I neuroprotection in dorsal root ganglia neurons , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  R. Medema,et al.  Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. , 2004, Molecular cell.

[43]  P. Morin,et al.  Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[44]  W. Dalton,et al.  Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death , 2003, Oncogene.

[45]  A. Martelli,et al.  Threonine 308 phosphorylated form of akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin , 2003, Journal of cellular physiology.

[46]  D. Altieri,et al.  Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. , 2002, Journal of cell science.

[47]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D R Alessi,et al.  Mitogenic Activation, Phosphorylation, and Nuclear Translocation of Protein Kinase Bβ* , 1997, The Journal of Biological Chemistry.

[49]  P. Cheah.  Recent advances in colorectal cancer genetics and diagnostics. , 2009, Critical reviews in oncology/hematology.

[50]  R. Moriggl,et al.  Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. , 2007, Neoplasia.